BRAF and non-small cell lung carcinoma: In metastatic NSCLC, dabrafenib plus trametinib was approved as a first-line treatment for patients with BRAF V600E-mutant metastatic NSCLC based on a phase II study showing a median PFS of 10.2 months and OS of 18.2 months in previously treated patients and a median PFS of 10.8 months and OS of 17.3 months in treatment-naïve patients [67].